This is an open label pre-post study of the effects of clinical treatment with varenicline on 1) decreasing smoking in schizophrenic patients, 2) improving selected cognitive measures in schizophrenic patients, and 3) psychopathology in schizophrenic patients. Patients are assessed on subjective and objective measures of smoking, selected cognitive measures, and special chemical measures, during baseline testing and during 8 weeks of treatment with varenicline (1-2 mg/day).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Self Report of Smoking
Timeframe: Baseline and during 2 months of treatment
CO (Carbon Monoxide) Breathalyzer Level
Timeframe: baseline and during 2 months of treatment
Plasma Cotinine
Timeframe: baseline 1 month and 2 months